Your browser doesn't support javascript.
loading
A novel dynamic model for predicting outcome in patients with hepatitis B virus related acute-on-chronic liver failure.
Xue, Ran; Duan, Zhonghui; Liu, Haixia; Chen, Li; Yu, Hongwei; Ren, Meixin; Zhu, Yueke; Jin, Chenggang; Han, Tao; Gao, Zhiliang; Meng, Qinghua.
Afiliação
  • Xue R; Department of Critical Care Medicine of Liver Disease, Beijing You-An Hospital, Capital Medical University, Beijing, China.
  • Duan Z; Department of Critical Care Medicine of Liver Disease, Beijing You-An Hospital, Capital Medical University, Beijing, China.
  • Liu H; Department of Critical Care Medicine of Liver Disease, Beijing You-An Hospital, Capital Medical University, Beijing, China.
  • Chen L; Georgia Prevention Institute, Medical College of Georgia, Augusta University, Augusta, GA, USA.
  • Yu H; Department of Critical Care Medicine of Liver Disease, Beijing You-An Hospital, Capital Medical University, Beijing, China.
  • Ren M; Department of Critical Care Medicine of Liver Disease, Beijing You-An Hospital, Capital Medical University, Beijing, China.
  • Zhu Y; Department of Critical Care Medicine of Liver Disease, Beijing You-An Hospital, Capital Medical University, Beijing, China.
  • Jin C; The School of Social Development and Public Policy, Beijing Normal University, Beijing, China.
  • Han T; Department of Hepatology, Tianjin Third Central Hospital of Tianjin Medical University, Tianjin, China.
  • Gao Z; Department of Infectious Diseases, The Third Affiliated Hospital, Zhongshan University, Guangzhou, China.
  • Meng Q; Department of Critical Care Medicine of Liver Disease, Beijing You-An Hospital, Capital Medical University, Beijing, China.
Oncotarget ; 8(65): 108970-108980, 2017 Dec 12.
Article em En | MEDLINE | ID: mdl-29312583
ABSTRACT

AIM:

It is challenging to predict the outcome of patients with hepatitis B virus related acute-on-chronic liver failure (HBV-ACLF) through existing prognostic models. Our aim was to establish a novel dynamic model to improve the predictive efficiency of 30-day mortality in HBV-ACLF patients.

METHODS:

305 patients who were diagnosed as HBV-ACLF (derivation cohort, n=211; validation cohort, n=94) were included in this study. The HBV-ACLF dynamic (HBV-ACLFD) model was constructed based on the daily levels of predictive variables in 7 days after diagnosis combined with baseline risk factors by multivariate logistic regression analysis. The HBV-ACLFD model was compared with the Child-Turcotte-Pugh (CTP) score, end-stage liver disease (MELD) score, and MELD within corporation of serum sodium (MELD-Na) score by the area under the receiver-operating characteristic curves (AUROC).

RESULTS:

The HBV-ACLFD model demonstrated excellent discrimination with AUROC of 0.848 in the derivation cohort and of 0.813 in the validation cohort (p=0.620). The performance of the HBV-ACLFD model appeared to be superior to MELD score, MELD-Na score and CTP score (P<0.0001).

CONCLUSION:

The HBV-ACLFD model can accurately predict 30-day mortality in patients with HBV-ACLF, which is helpful to select appropriate clinical procedures, so as to relieve the social and economic burden.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article